

Diabetes mellitus

Aetiology and Pathogenesis, Specific complications

Darja Krusova
II dpt. of internal med. FNUSA

Diabetes mellitus


- chronic metabolic and endocrine disorder
- due to insufficiency of insulin action
- blood glucose level - permanent increased hyperglycaemia and glycosuria

in Czech Rep.: more than 9,5%=960.000 diabetics
-92% DM type 2


1995- 504.000 diabetics, 1975- 250.000

children: 4,3% till 15 y., 6,9% till 6 y.


USA: 11% > 20r., 28% >65r. (prediab.50% > 65r, 35% > 20r.)



Number of treated diabetic patients in Czech rep.



Structure of a pancreatic islet



Biosynthesis of insulin

Gen-11-th chromosoma


👉 preproinsulin

👉 proinsulin


👉 insulin + C peptid (30-120 min)

👉 receptors

-depends on insulin level, p.o. antidiabetic drugs




Biosynthesis of insulin



Primary structure of human insulin


A chain



B chain



	B30	A8	A10
Human	Thr	Thr	Ile
Porcine	Ala	Thr	Ile
Bovine	Ala	Ala	Val



Insulin secretion





☞ **Basal**- cca 20 U/day

☞ **Stimulated**- after secretional stimuli

★ **fast, first phase** - mediated through hormones (GIP, GLP-1) - 5-10 min


🕒 **prolonged, second phase** - depends on nutritional stimuli,

takes all the time of its duration, max 2-3 h.



Lower action of insulin 1


- ☞ absence of insulin output in B-cells
- ☞ defect in synthesis of ins. /proins., decrease ins.production, output of faulty insulin
- ☞ insulin releasing defect
- ☞ defect due to antibodies
- ☞ defect of ins.action in target organs (receptors)
- ☞ defect in insulin degradation
- ☞ increased action of insulin's antagonists



hyperglycaemia

Lower action of insulin 2

- ☞ Reduction of intra-cell transport of glucose
- ☞ increase in gluconeogenesis
decrease in glycolysis in liver
- ☞ increase in glycogenolysis



hyperglycaemia

Insulin action

Increased intra-cell transport of glu,
aminoacids, K, Mg, Ca

▣ of glucose-transporters GLUT-4

▣ 30-60% gl utilized in liver

→ Stimulation of anabolic and block of
catabolic processes in organism


Insulin actions 1

Liver:

- ☞ increase in synthesis of glycogen - anabol.effect
- ☞ increased intake of glu into the cells and its utilisation in peripherie
- ☞ decrease in glukoneogenesis a glykogenolysis
 - anticatabol.effect
 - decreased glycaemia

Insulin actions 2

- ☞ increase in synthesis of lipids- lipogenesis
decreased lipolysis- antilipolytic action
antiketogen. action
- ☞ increase in synthesis of proteins-anabol. action
increase in RNA syntesis
decreased proteolysis- anticatabol. action



Insulin deficiency 1

☞ In corporal cells

block of gluc. and aminoacids - transport intracell.

↓ peripheral gluc.utilisation
↓ proteosynthesis

☞ In liver

↑ glykogenolysis
↑ glukoneogenesis
↑ proteolysis
↑ occur. of amnoacids

↑ production of glu
↑ production of urea
↑ production of fat and lipoproteins
↑ production ketoacids

Insulin deficiency 2

☞ In fatty tissue

↑ lipolysis

↓ lipogenesis

— ↑ fatty acids

☞ In muscle
preferential utilisation
of proteins and fats

— ↑ offer of aminoacids
and fatty acids for liver

Contraregulatory hormones

- 👉 **Glukagon-A** increases glycogen-splitting in liver
- 👉 **STH,GH** decreases glucose utilisation
- 👉 **ACTH** increases glucocort.
- 👉 **Glucocorticoids** increases glukoneogenesis, stim.Of insulin, decreases peripheral glucose utilisation
- 👉 **Adrenalin** increases glykogenolysis in muscle, decreases insulin secretion
- 👉 **Hormons of thyreoid gland**
- 👉 **Somatostatin -D** decreases insulin secretion
- Pancreatic polypeptid ,VIP , Amylin -B** decreases insulin secretion

DM classification ¹

- 1 DM type 1 a) immune
absolute insulin deficit b) idiopathic
 LADA, brittle
- 2 DM type 2 insulin resistance
relative insulin deficit

DM classification 2

3 Other specific types

- ▶ genetic defects of B-cells function: MODY
(autosomal domin. inheritance ,younger age,asthenics,without insulin necessity.)
- ▶ genetic defects of insulin action
- ▶ disease of exocrine part of pancreas
- ▶ endocrinopathies
- ▶ drugs induced
- ▶ viral infection (cong. rubeola, CMV, ...)
- ▶ rare immunologically caused
- ▶ other genetic sy (Down, Klinefelter, ...)

4 Gestational DM

I

II

Age of manifestation	childhood-40	middle, older, >40
habitus	asthenic	hyperstenic
haplotyps	DR3,DR4,DQ	-
ins.synthesis	↓ - 0	norm.
insulinaemia	↓ - 0	norm,
autoantibodies	↓ +	- ↑
response on PAD	-	+
glycaemia	brittle	relat. stable
onset of disorder	quick /weeks/	slow (months-years)
symptoms	severe	mild or none
ketoacidosis	+	↓
insulin therapy	+	PAD, diet, insulin-resistance
vascul.complications	micro	macro

Pathogenesis of DM 1.type

Eisenbarth's scheme

1. Genetic susceptibility

DR3,DR4

2. Initiating mechanism

Coxsackie B

mumps, rubeolla, CMV

EBV

3. Incipient insulinitis

/ICA,ICSA,IA-2,GADA/

/IAA,PAA,ICSTA/

4. Full developed insulinitis (80%)

5. Manifestation of diabetes

6. No secretion of endogenous insulin

↳ DM 1.type






Fig. 21.4 Pathogenesis of type 1 diabetes. Proposed sequence of events in the development of type 1 diabetes. Environmental triggers are

Pathogenesis of DM 2. type

(polygenic type of heredity-except MODY)



DM 2.type -contributing factors

fett meals

nutrition

- overeating

high age

live style

- stress, infection, operation
acute endangering situations
reduction of movement

alcohol

- pancreatitis, cirrhosis hepatis

iatrogenic DM

- corticosteroids, thiazids,
contraceptivs

gravidity

endocrine disorders

DG criteria

Clin.symptoms	fasting gly	gly/pp.	dg
thirst,polydipsia, polyuria, weight loss, total disability infection(skin,genitals) poorly healing wounds suddenly developed complication	> 7,0	> 11,1	DM
	< 7,0	5,7-11,1	IGT
		increased FPG, prediabetes	
No clin. sympt.	< 5,6	< 7,8	norm

Oral glucose tolerance test oGTT

norm.

IGT

DM

fasting value < 5,6 insignificant >7

2-hour value < 7,8 7,8- 11,0 >11,1

Laboratory examinations

Glycaemia -fasting value glycosuria
 -postprandial value ketonuria
 -glycaemic profil

Glycated hemoglobin (HbA₁C)

(fructosamin)

C peptid

Insulinaemia = IRI

insulin antibodies (IA₂,GADA)

biochemistry tests, lipids

DCCT	IFCC (mmol/mol)	IFCC %
4	20	2.0
4.5	26	2.6
5	31	3.1
5.5	37	3.7
6	42	4.2
6.5	48	4.8
7	53	5.3
7.5	58	5.8
8	64	6.4
8.5	69	6.9
9	75	7.5
9.5	80	8.0
10	86	8.6
10.5	91	9.1
11	97	9.7
11.5	102	10.2
12	108	10.8
12.5	113	11.3
13	119	11.9

zdraví lidé: 28-42 mmol/mol

**ČDS: výborná kompenzace:
<45 mmol/mol**

ADA doporučení: <7.0% (DCCT)

**ISPAD doporučení: < 58 mmol/
mol**

**ČDS: uspokojivá kompenzace:
<60 mmol/mol**

Complications

- **Acute** ~ hypoglycaemic coma
 - ~ hyperglycaemic coma -with ketoacidosis
 - hyperosmolar without ketoacidosis
 - ~ laktacidotic coma
- **Chronic**
- **Imunoallergic - local** (lipodystrophia)

hypo

hyper

start

sudden

slow

symptoms

nervosity shivering,agitation,
hunger,sweating

nausea, vomitus,
dehydration

insulin administration

precede

sometimes miss

thirst

-

+

cognition lost

sudden

slow

skin

wet

dry

skin turgor

normal

decreased

eyeball's tonus

normal

soft

breathing

normal

profound-Kussmaul

breath

without aceton

aceton

glycaemia

low

high

gl/u

-

++

ac/u

-

+

Complications

- Acute

- Chronic a/ specific

 - ~ microangiopathy- retina, kidney, foot

 - ~ neuropathy

 - b/ nonspecific

 - ~ makroangiopathy ~ dermatol. dis. ~ liver ~ other

- Imunoallergic




Fig. 21.15 The roles of hyperglycaemia-induced accumulation of reactive oxygen species and oxidative stress in causation of diabetic vascular complications. The induction of oxidative stress causes haemodynamic changes and endothelial and vascular dysfunction, leading to vascular damage.

Cardiovascular mortality

3x ↑ in diabetics than nondiabetics

37x ↑ in diabetics with nephropathy
than nondiabetics with nephropathy

Results of UKPDS

decrease in microvascular
complications

about **25%**

due to HbA₁C improvement

from 7,9 to 7,0%

(act. from 64 to 54 mmol/mol)

Diabetic neuropathy

- **Peripheral neuropathy**-abnormal and decreased sensation ('glove and stocking' distribution)
 - diabetic foot (neuropathy + angiopathy)
 - Charcot's Joint - neuropathic arthropathy
- Autonomic neuropathy - digestive system, urinary tract, sex organs,..
- mononeuritis
- Diabetic amyotrophy - muscle weakness due to neuropathy

Diabetic retinopathy

- Nonproliferative retinopathy
- Macular edema
- Proliferative retinopathy
 - growth of friable and poor-quality new blood vessels in the retina
- which can lead to severe vision loss or blindness (most common cause of blindness among non-elderly adults)

Diabetic nephropathy

- 👉 serious microangiopathic late complication of diabetes
- 👉 one of the most frequent causes of diabetics preterm death
- 👉 occurs in both types of diabetes
in 1/3 by type 1, less by type 2

Diabetic nephropathy

- 👉 chronic progressive renal disease
- 👉 proteinuria
- 👉 hypertension
- 👉 gradual decrease of renal functions


Etiopathogenesis

**Factors important
for the development of DN:**

 poor glycemic control

 hypertension

Hyperglycaemia



Microalbuminuria

Definition:

**MAU - excretion of alb/U,
which exceeds upper limit
of referential range for nondiabetics**

**Normally non detectable
with diagnostic proteinuric strips**

Stages of diabetic nephropathy

(Mogensen 1993)

Stage	Duration of DM-years	Laboratory	GF	Compli- cations
1.Latent hypertrophic hyperfunctional	at the same time with dg of DM	norm	hyperfiltration	0

reversible by the strict control of gly

Stages of diabetic nephropathy

(Mogensen 1993)


Stage	Duration of DM-years	Laboratory	GF	Compli- cations
2.Incipient	2 - 6	a)MAU intermitent -after phys.exer.	norm.	0
	7 - 15	b)MAU permanent 30-300 mg/24h		

a) hyperfiltration reduction by the gly control,
antihypert. drugs: reduction of MAU

b) reduction of MAU, decrease of GFR prevention

Stages of diabetic nephropathy

(Mogensen 1993)

Stage	Duration of DM-years	Laboratory	GF	Complications
3. Manifest	15 - 20	PU > 500 mg/24/h	about 1ml/min/month 	retinopathy neuropathy

gly control: irreversible

antihypertonic drugs: deceleration of progression

Stages of diabetic nephropathy

(Mogensen 1993)

Stage	Duration of DM-years	Laboratory	GF	Compli- cations
4. Chronic renal insufficiency	> 20	↑ S-krea ↑ S-urea ↑ S-uric acid	↓	progression of vascular compl.


End stage kidney

ACE inhibitors, RAS blockers


Effect: antihypertensive
cardioprotective
vasoprotective


👉 **in diabetics:** action metabolic,
antiproliferative, paracrine and
specific nephroprotective .

Renin-angiotenzinový systém




Therapy algorithm in diabetics with MAU

Diabetes control **N**  control correction

correct? **Y** 

Start of therapy **RAS blockers** 

Undesirable effects/ pregnancy- **Y**  stop. Other antihypert.


N 

drugs

TK < 130/85 + decrease MAU - **N**  therapy of hypert.

Y 


(add)

Repeat MAU each 3-6 m.  Risk factor elimination

Goal: stable GFR. Stable/decreasing MAU. BP.



Fig. 60.1 Necrobiosis lipoidica diabetorum (NLD). (a) An early lesion on an ankle, showing the erythematous stage. (b) A long-standing patch of NLD. Note the typical yellow, atrophic appearance with telangiectasia.



xanthelasma palpebrarum



gangraena sicca



Dupuytrain's contracture





vitreous hemorrhagy